TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31335572

Group type: EXPERIMENTAL
Intervention: NBP607-QIV
Number of subjects: 454

Group type: COMPARATOR
Intervention: Control (inactivated trivalent influenza vaccine)
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: NBP607-QIV and Control
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: Solicited AEs for both groups
Number of subjects: 454
Study: 27801753

Group type: EXPERIMENTAL
Intervention: Higher enteral protein intake (1 g/100 mL expressed breast milk)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Lower enteral protein intake (0.4 g/100 mL expressed breast milk)
Number of subjects: 120
Study: 26192873

Group type: EXPERIMENTAL
Intervention: Immediate-initiation group
Number of subjects: 4685

Group type: COMPARATOR
Intervention: Deferred-initiation group
Number of subjects: 4685

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 4685
Study: 23792541

Group type: EXPERIMENTAL
Intervention: Clonidine (100 μg)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 21726586

Group type: EXPERIMENTAL
Intervention: TM-Sidhi practice
Number of subjects: 2

Group type: COMPARATOR
Intervention: TM practice
Number of subjects: 2
Study: 18923805

Group type: EXPERIMENTAL
Intervention: Gynemesh PS
Number of subjects: 190

Group type: COMPARATOR
Intervention: Pelvicol
Number of subjects: 190
Study: 16407905

Group type: EXPERIMENTAL
Intervention: Amino-acid drink containing l-tryptophan (T+)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amino-acid drink without l-tryptophan (T-)
Number of subjects: 0
Study: 12937048

Group type: EXPERIMENTAL
Intervention: Preterm infants
Number of subjects: 39
Study: 16422035

Group type: EXPERIMENTAL
Intervention: Standard oral hygiene regimen
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Statistical analysis techniques (Standard Normal Deviate, elimination of outliers)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Initial screening and professional prophylaxis
Number of subjects: 63

Group type: COMPARATOR
Intervention: Random assignment to test and control groups
Number of subjects: 63
Study: 9510924

Group type: EXPERIMENTAL
Intervention: Autologous blood transfusion using cell salvage
Number of subjects: 100

Group type: COMPARATOR
Intervention: Allogeneic blood transfusion
Number of subjects: 100
Study: 8090337

Group type: EXPERIMENTAL
Intervention: Misoprostol (400 micrograms/day for 12 months)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (aluminium and magnesium hydroxide)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Misoprostol + group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Misoprostol-group
Number of subjects: 60
Study: 3045281

Group type: EXPERIMENTAL
Intervention: Naloxone (approximately 0.4 mg/kg)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 193
Study: 30383458

Group type: EXPERIMENTAL
Intervention: Game group (serious game 'Hit the Cancer', 30 minutes/day, 5 days/week for 3 weeks)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Nongame group (usual care)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Game group
Number of subjects: 35

Group type: COMPARATOR
Intervention: Nongame group
Number of subjects: 35
Study: 25588153

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Adherence and Depression (CBT-AD)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Enhanced treatment as usual
Number of subjects: 89
Study: 23937067

Group type: EXPERIMENTAL
Intervention: Resistant starch and Lactobacillus acidophilus yoghurt (LC1)
Number of subjects: 19
Study: 21340377

Group type: EXPERIMENTAL
Intervention: Respiratory muscle training (RMT)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (CO)
Number of subjects: 38
Study: 18181252

Group type: EXPERIMENTAL
Intervention: ABIO-08/01 (40 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 15879169

Group type: EXPERIMENTAL
Intervention: Heat extraction device (local subatmospheric pressure 35‐45 mmHg and heat sink 18‐22 degrees C)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Heat extraction device
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (no device)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Cooling only (hand cooling)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Cooling and subatmospheric pressure
Number of subjects: 8
Study: 12935434

Group type: EXPERIMENTAL
Intervention: Amoxicilina 500 mg capsules
Number of subjects: 24

Group type: COMPARATOR
Intervention: Amoxil 500 mg capsules
Number of subjects: 24
Study: 11092517

Group type: EXPERIMENTAL
Intervention: Pulsatile intravenous insulin therapy (PIVIT) in addition to intensive therapy (IT)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Intensive therapy (IT)
Number of subjects: 49
Study: 9414440

Group type: EXPERIMENTAL
Intervention: Nitric oxide (NO)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 1957968

Group type: EXPERIMENTAL
Intervention: Flunarizine (FLN) administered as drops in a single evening dose of 5 mg (patients <10 years) or 10 mg (patients >10 years)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 6274476

Group type: EXPERIMENTAL
Intervention: Selective venous catheterisation and sampling for ACTH
Number of subjects: 23
Study: 31649275

Group type: EXPERIMENTAL
Intervention: Survey on perception of wildfire smoke hazards
Number of subjects: 2237
Study: 28847532

Group type: EXPERIMENTAL
Intervention: Restricted energy availability (RES; 15kcal·kgLBM‐1·d‐1)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Controlled energy availability (CON; 45kcal·kgLBM‐1·d‐1)
Number of subjects: 22
Study: 25811674

Group type: EXPERIMENTAL
Intervention: Beetroot juice (BR) 70 mL (6 mmol nitrate)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo (nitrate-depleted BR)
Number of subjects: 11
Study: 24268099

Group type: EXPERIMENTAL
Intervention: Day-hospital-based treatment programme combining individual and group psychotherapy in a step-down format
Number of subjects: 107

Group type: COMPARATOR
Intervention: Outpatient individual psychotherapy at a specialist practice
Number of subjects: 107
Study: 20642462

Group type: EXPERIMENTAL
Intervention: Child Drawing: Hospital (CD:H) score
Number of subjects: 54

Group type: COMPARATOR
Intervention: Frankl scale
Number of subjects: 54

Group type: COMPARATOR
Intervention: SEM scale
Number of subjects: 54
Study: 19813463

Group type: EXPERIMENTAL
Intervention: Piroxicam patch (14 mg, 1%, applied once daily)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Piroxicam cream (1%, applied three times a day)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo patch (applied once daily)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Piroxicam patch vs Piroxicam cream
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Piroxicam patch vs Piroxicam cream (intermediate visit, day 4)
Number of subjects: 180
Study: 17448820

Group type: EXPERIMENTAL
Intervention: Enoxaparin 40 mg subcutaneously once daily for 10 days
Number of subjects: 1762

Group type: COMPARATOR
Intervention: Unfractionated heparin 5000 U subcutaneously every 12 h for 10 days
Number of subjects: 1762

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 1762

Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 1762
Study: 15100670

Group type: EXPERIMENTAL
Intervention: Seasonal allergic rhinitis patients
Number of subjects: 50

Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 50
Study: 11570706

Group type: EXPERIMENTAL
Intervention: QSART
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: SSR
Number of subjects: 31
Study: 9663476

Group type: EXPERIMENTAL
Intervention: Low-dose prednisolone treatment
Number of subjects: 79
Study: 8005549

Group type: EXPERIMENTAL
Intervention: Oral placebo
Number of subjects: 56

Group type: COMPARATOR
Intervention: Intramuscular placebo
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Progestogen withdrawal test responsive patients
Number of subjects: 56

Group type: COMPARATOR
Intervention: Progestogen withdrawal test nonresponsive patients
Number of subjects: 56
Study: 2908303

Group type: EXPERIMENTAL
Intervention: Carvedilol 50mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carvedilol 100mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Labetalol 400mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propranolol 160mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propranolol 80mg plus Hydralazine 50mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydralazine plus Propranolol 80mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cold pressor and isometric exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31188820

Group type: EXPERIMENTAL
Intervention: Praziquantel treatment
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: Hookworm infection
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: Elevated IL-6, IL-10, and CXCL8 in cord blood
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: Elevated sTNFRI in cord blood and IL-5 in placental blood
Number of subjects: 369
Study: 28166743

Group type: EXPERIMENTAL
Intervention: Molecular point-of-care testing using the FilmArray Respiratory Panel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine clinical care
Number of subjects: 0
Study: 25408122

Group type: EXPERIMENTAL
Intervention: Center of Rotation (COR) measurement for L4 motion segment in y axis
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Center of Rotation (COR) measurement for L5 motion segment in y axis
Number of subjects: 66
Study: 24289509

Group type: EXPERIMENTAL
Intervention: Intravenous paracetamol
Number of subjects: 700

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 700
Study: 21611733

Group type: EXPERIMENTAL
Intervention: Positive interpretation training
Number of subjects: 170

Group type: COMPARATOR
Intervention: Placebo-control condition
Number of subjects: 170
Study: 18381903

Group type: EXPERIMENTAL
Intervention: Adjunctive aripiprazole (15 or 30 mg/day)
Number of subjects: 384

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 384
Study: 16449030

Group type: EXPERIMENTAL
Intervention: Loop diuretics, aminoglycosides, neuromuscular blockers (NMB), and vancomycin (50 received vancomycin)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Cumulative dosages and duration of use of diuretics, NMB, vancomycin, and overlap of diuretics with NMB, aminoglycosides, and vancomycin
Number of subjects: 81

Group type: COMPARATOR
Intervention: Markers of illness severity
Number of subjects: 81

Group type: COMPARATOR
Intervention: Aminoglycosides
Number of subjects: 81
Study: 12914886

Group type: EXPERIMENTAL
Intervention: Metoprolol CR/XL
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 10899732

Group type: EXPERIMENTAL
Intervention: Acamprosate
Number of subjects: 448

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 448
Study: 9179560

Group type: EXPERIMENTAL
Intervention: 1 g dispersible tablet form of amoxicillin (B)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 1 g dispersible tablet in suspension form (C)
Number of subjects: 12

Group type: COMPARATOR
Intervention: 1 g standard reference formulation (A)
Number of subjects: 12
Study: 1564142

Group type: EXPERIMENTAL
Intervention: Vaseline Petroleum Jelly (VPJ)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated sites
Number of subjects: 0
Study: 4018467

Group type: EXPERIMENTAL
Intervention: Lidocaine (L) - bolus of 1 mg/kg followed by an infusion of 10 mg/min for 20 minutes and thereafter of 1.5 mg/min
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Amiodarone (A) - bolus of 5 mg/kg and an eventual repeat dose of 150 mg followed by an infusion of 1.8 g/24 h
Number of subjects: 25

Group type: COMPARATOR
Intervention: Lidocaine (L)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Amiodarone (A)
Number of subjects: 25
Study: 29317118

Group type: EXPERIMENTAL
Intervention: PXVX0200 (1 × 10^9 CFU)
Number of subjects: 3146

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 3146

Group type: EXPERIMENTAL
Intervention: PXVX0200
Number of subjects: 3146

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3146
Study: 26749407

Group type: EXPERIMENTAL
Intervention: Ranolazine 1000mg twice daily added to glimepiride
Number of subjects: 873

Group type: EXPERIMENTAL
Intervention: Ranolazine 1000mg twice daily added to metformin
Number of subjects: 873
Study: 24878030

Group type: EXPERIMENTAL
Intervention: G3 on pre-hospital ECG
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: G2->G2
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: G2->G3
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: G3->G3
Number of subjects: 401

Group type: COMPARATOR
Intervention: G3
Number of subjects: 401

Group type: COMPARATOR
Intervention: G2
Number of subjects: 401
Study: 23025057

Group type: EXPERIMENTAL
Intervention: 24-week peginterferon alpha-2a (180 microg/week) plus ribavirin therapy (group A)
Number of subjects: 102

Group type: COMPARATOR
Intervention: 48-week peginterferon alpha-2a (180 microg/week) plus ribavirin therapy (group B)
Number of subjects: 102
Study: 20434863

Group type: EXPERIMENTAL
Intervention: Brief motivational intervention for smoking cessation including spirometric testing and feedback (approximately 20 min)
Number of subjects: 267
Study: 17637912

Group type: EXPERIMENTAL
Intervention: Chimney woodstove intervention
Number of subjects: 120

Group type: COMPARATOR
Intervention: Traditional open wood fire
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Improved stove intervention
Number of subjects: 120

Group type: COMPARATOR
Intervention: Chimney woodstove intervention (before-and-after comparison)
Number of subjects: 120
Study: 15691684

Group type: EXPERIMENTAL
Intervention: Dobutamine (5 microg/kg per min)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (no dobutamine)
Number of subjects: 32
Study: 12107618

Group type: EXPERIMENTAL
Intervention: 10 mg ritanserin
Number of subjects: 22

Group type: COMPARATOR
Intervention: 0.1 mg/kg mCPP
Number of subjects: 22

Group type: COMPARATOR
Intervention: mCPP
Number of subjects: 22
Study: 10460529

Group type: EXPERIMENTAL
Intervention: Hemispheric-synchronised sounds
Number of subjects: 76

Group type: COMPARATOR
Intervention: Classical music
Number of subjects: 76

Group type: COMPARATOR
Intervention: Blank tape
Number of subjects: 76
Study: 7876865

Group type: EXPERIMENTAL
Intervention: [18F] fluorodeoxyglucose‐PET (FDG‐PET)
Number of subjects: 39

Group type: COMPARATOR
Intervention: MRI
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: MRI and PET
Number of subjects: 39
Study: 2404020

Group type: EXPERIMENTAL
Intervention: Pneumatic sequential-compression boots
Number of subjects: 119

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 119
Study: 47348

Group type: EXPERIMENTAL
Intervention: Group classes utilizing audiovisual teaching techniques
Number of subjects: 45

Group type: COMPARATOR
Intervention: Traditional bedside manner
Number of subjects: 45
Study: 30824825

Group type: EXPERIMENTAL
Intervention: Dialysis patients
Number of subjects: 160

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 160
Study: 28436395

Group type: EXPERIMENTAL
Intervention: Intranasal 200 mg GSH
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Intranasal 100 mg GSH
Number of subjects: 45

Group type: COMPARATOR
Intervention: Intranasal placebo (saline)
Number of subjects: 45
Study: 25251411

Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine gel applied to one-half of the sockets
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control (no chlorhexidine gel)
Number of subjects: 45
Study: 23995467

Group type: EXPERIMENTAL
Intervention: Innovative teaching strategies
Number of subjects: 209
Study: 21281463

Group type: EXPERIMENTAL
Intervention: Irinotecan 80 mg/m2 i.v., LV 200 mg/m2, 5FU 450 mg/m2 bolus (Arm A)
Number of subjects: 873

Group type: COMPARATOR
Intervention: Leucovorin 200 mg/m2 and 5FU 500 mg/m2 i.v. bolus (Arm B)
Number of subjects: 873
Study: 19100248

Group type: EXPERIMENTAL
Intervention: Cyclosporine (CyA)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Tacrolimus (Tac)
Number of subjects: 35
Study: 16733624

Group type: EXPERIMENTAL
Intervention: 1 g of calcium daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 15359015

Group type: EXPERIMENTAL
Intervention: Corrective entreaty
Number of subjects: 160

Group type: COMPARATOR
Intervention: Hypothetical referendum
Number of subjects: 160

Group type: COMPARATOR
Intervention: Real payment referendum
Number of subjects: 160
Study: 10862195

Group type: EXPERIMENTAL
Intervention: Multimodal rehabilitation program including continuous thoracic epidural analgesia, enforced early mobilization, and early enteral nutrition with a planned 48‐hour postoperative hospital stay.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group not explicitly mentioned, but implied standard postoperative care with longer hospital stay.
Number of subjects: 60
Study: 9347367

Group type: EXPERIMENTAL
Intervention: NIPSV (BiPAP)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Standard treatment (Control)
Number of subjects: 42
Study: 8155035

Group type: EXPERIMENTAL
Intervention: Pentoxifylline at 2000 mg/d
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2872806

Group type: EXPERIMENTAL
Intervention: Terazosin
Number of subjects: 133

Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 133

Group type: COMPARATOR
Intervention: Prazosin
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Terazosin plus Hydrochlorothiazide
Number of subjects: 133
Study: 30458866

Group type: EXPERIMENTAL
Intervention: Umeclidinium bromide/vilanterol (UMEC/VI) 62.5/25 mcg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tiotropium/olodaterol (TIO/OLO) 5/5 mcg
Number of subjects: 0
Study: 26599131

Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone
Number of subjects: 1080

Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 1080
Study: 24377455

Group type: EXPERIMENTAL
Intervention: Bayberry juice (250 mL twice daily for 4 weeks)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 22210566

Group type: EXPERIMENTAL
Intervention: intralipid/heparin infusion
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: high-fat meal
Number of subjects: 38
Study: 20082173

Group type: EXPERIMENTAL
Intervention: Communication skills training programs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical workload and overuse of facilitative communication skills
Number of subjects: 0
Study: 18343810

Group type: EXPERIMENTAL
Intervention: Transvaginal aspiration of hydrosalpinx under antibiotics cover
Number of subjects: 66

Group type: COMPARATOR
Intervention: No aspiration (control group)
Number of subjects: 66
Study: 16266355

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg once daily (QD)
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg twice daily (BID)
Number of subjects: 348

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg BID
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg QD
Number of subjects: 348
Study: 12443948

Group type: EXPERIMENTAL
Intervention: Unexpected forward perturbations (FP) during gait
Number of subjects: 0
Study: 10343535

Group type: EXPERIMENTAL
Intervention: Home based exercise programme (n = 113)
Number of subjects: 191

Group type: COMPARATOR
Intervention: No intervention (control group, n = 78)
Number of subjects: 191
Study: 8949694

Group type: EXPERIMENTAL
Intervention: 10% lipid emulsion
Number of subjects: 75

Group type: COMPARATOR
Intervention: 20% lipid emulsion
Number of subjects: 75
Study: 1827008

Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 160

Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 160
Study: 6123638

Group type: EXPERIMENTAL
Intervention: 10 degrees reverse Trendelenburg position
Number of subjects: 10

Group type: COMPARATOR
Intervention: Semi-orthopnoeic position (control)
Number of subjects: 10
Study: 31563697

Group type: EXPERIMENTAL
Intervention: Letrozole (LE) combined with low-dose gonadotropins using the multiple-dose GnRH-antagonist protocol
Number of subjects: 51

Group type: COMPARATOR
Intervention: Low-dose gonadotropins using the multiple-dose GnRH-antagonist protocol (Control Group A)
Number of subjects: 51
Study: 31421524

Group type: EXPERIMENTAL
Intervention: Consume 3 dairy servings/day
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Consume ≥ 4 servings/d
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3
Study: 27037817

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine administered as short intravenous infusion of 1-2 µg/kg in 10 min
Number of subjects: 39

Group type: COMPARATOR
Intervention: Dexmedetomidine
Number of subjects: 39
Study: 26063001

Group type: EXPERIMENTAL
Intervention: Gynocular colposcope
Number of subjects: 123

Group type: COMPARATOR
Intervention: Stationary colposcope
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Punch biopsy
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Cytology
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Gynocular and stationary colposcope
Number of subjects: 123
Study: 23375053

Group type: EXPERIMENTAL
Intervention: Self-ligating brackets
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Conventional brackets
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both treated groups (self-ligating and conventional)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 21632986

Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted vaccine
Number of subjects: 0
Study: 19101312

Group type: EXPERIMENTAL
Intervention: Thermogard system
Number of subjects: 38

Group type: COMPARATOR
Intervention: Conventional warming
Number of subjects: 38
Study: 16213663

Group type: EXPERIMENTAL
Intervention: Depressed patients (hypercortisolemic)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Depressed patients (normocortisolemic)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Normocortisolemic patients
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Hypercortisolemic patients
Number of subjects: 29
Study: 15558380

Group type: EXPERIMENTAL
Intervention: Physical Practice (PP)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Motor Imagery-based Mental Practice (MP)
Number of subjects: 39

Group type: COMPARATOR
Intervention: No Practice (NP)
Number of subjects: 39